Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of May 2019, specifically dated May 23, 2019. The registrant is a foreign private issuer based in Petach-Tikva, Israel, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses on a specific corporate development regarding the company's clinical research program.
Outlook, Management Commentary, and Risks
On May 23, 2019, the company announced that its investigational drug, Namodenoson, was selected for a podium presentation in the "Selected Abstracts of Excellence" session at the 2nd Annual International Conference on Fatty Liver (ICFL 2019) in Berlin, Germany (June 27-29, 2019). The presentation title is "Namodenoson anti-NAFLD/NASH Activity is Mediated via De-regulation of the Wnt/β-catenin Pathway." The press release attached as Exhibit 99.1 contains forward-looking statements incorporated by reference into the company's Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed clinical data.
- Confirm the specific date and location of the ICFL 2019 conference presentation.
- Review the "Forward Looking Statements" section within the attached press release for associated risks.
- Check subsequent filings for the outcome of the presentation and any updated clinical trial timelines.